NantOmics
Industry / private company
Location:
Culver City, CA,
United States (USA) (US)
ISNI: 0000000449049016
ROR: https://ror.org/0121y9f76
Show on Map:
Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial (2023)
Williams TM, Schneeweiss A, Jackisch C, Shen C, Weber KE, Fasching P, Denkert C, et al.
Journal article
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial (2023)
Fasching P, Szeto C, Denkert C, Benz S, Weber K, Spilman P, Budczies J, et al.
Journal article
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy☆ (2021)
Denkert C, Untch M, Benz S, Schneeweiss A, Weber KE, Schmatloch S, Jackisch C, et al.
Journal article